Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Recommendation of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $13.40.

A number of analysts have recently commented on HCAT shares. Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, August 29th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Thursday, September 14th. Evercore ISI cut their target price on shares of Health Catalyst from $14.00 to $10.00 in a research report on Wednesday, October 11th. Stifel Nicolaus cut their target price on shares of Health Catalyst from $15.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, November 1st. Finally, Royal Bank of Canada cut their target price on shares of Health Catalyst from $13.00 to $8.00 and set a “sector perform” rating for the company in a research report on Monday, October 30th.

Insider Activity at Health Catalyst

In related news, CAO Jason Alger sold 2,197 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $11.65, for a total transaction of $25,595.05. Following the sale, the chief accounting officer now owns 56,942 shares of the company’s stock, valued at $663,374.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold a total of 5,675 shares of company stock valued at $61,366 over the last 90 days. 2.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Health Catalyst

Hedge funds have recently bought and sold shares of the business. Summit Global Investments purchased a new stake in Health Catalyst during the first quarter valued at $208,000. WCM Investment Management LLC increased its position in Health Catalyst by 7.5% during the second quarter. WCM Investment Management LLC now owns 635,574 shares of the company’s stock valued at $7,919,000 after acquiring an additional 44,432 shares during the last quarter. American Century Companies Inc. increased its position in Health Catalyst by 2.0% during the first quarter. American Century Companies Inc. now owns 583,035 shares of the company’s stock valued at $6,804,000 after acquiring an additional 11,221 shares during the last quarter. Nepsis Inc. increased its position in Health Catalyst by 6.2% during the second quarter. Nepsis Inc. now owns 842,739 shares of the company’s stock valued at $10,534,000 after acquiring an additional 49,160 shares during the last quarter. Finally, First Light Asset Management LLC increased its position in Health Catalyst by 70.4% during the first quarter. First Light Asset Management LLC now owns 1,980,317 shares of the company’s stock valued at $23,110,000 after acquiring an additional 818,322 shares during the last quarter. Hedge funds and other institutional investors own 86.63% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $7.75 on Thursday. The company has a 50 day moving average price of $8.70 and a 200-day moving average price of $10.84. Health Catalyst has a 52 week low of $6.60 and a 52 week high of $15.87. The firm has a market capitalization of $446.01 million, a PE ratio of -3.48 and a beta of 1.36. The company has a quick ratio of 4.85, a current ratio of 4.85 and a debt-to-equity ratio of 0.60.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases.